Statins and diabetes mellitus: price of collaboration
https://doi.org/10.14341/2072-0351-5522
Abstract
It is now well established that clinical use of statins for primary and secondary prevention of cardiovascular complications in patientswith diabetes mellitus (DM) increases life expectancy. At the same time, meta-analysis of major randomized trials shows statins to increaseglycemic levels and incidence of diabetic symptoms, especially in patients at risk for developing glycemic disorders. However,comparison of positive and negative effects of statins suggests prevalence of clinically beneficial factors.
About the Authors
Andrey Alexeevich Aleksandrov
Endocrinology Research Centre, Moscow
Maria Nikolaevna Yadrikhinskaya
Endocrinology Research Centre, Moscow
Svetlana Semenovna Kukharenko
Endocrinology Research Centre, Moscow
Olga Alexandrovna Shatskaya
Endocrinology Research Centre, Moscow
References
1. Standards of Medical Care in Diabetes-2010. American Diabetes Association. Diabetes Care. 2010 Jan;33 Suppl 1:S11-S61.
2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией Дедова ИИ, Шестаковой МВ. Издание четвертое дополненное. М; 2009.
3. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации IV пересмотр. Разработан Комитетом экспертов Всероссийского научного общества кардиологов (ВНОК). Москва; 2009.
4. Задионченко ВС, Шахрай НБ и соавторы. Особенности фармакологических и клинических свойств розувастатина. РМЖ. 2011;19(12).
5. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007 Nov 29;357(22):2248-2261. Epub 2007 Nov 5
6. Kanda M, Satoh K, Ichihara K. Effects of Atorvastatin and Pravastatin on Glucose Tolerance in Diabetic Rats Mildly Induced by Streptozotocin. Biol Pharm Bull. 2003; 26:1681-1684.
7. Murakami T, Mizuno K. Two patients whose diabetes mellitus deteriorated after the administration of atorvastatin and for whom intensive insulin therapy was instituted. J Cardiol. 2003; 42:Suppl.1:455.
8. Sasaki J, Iwashita M, Kono S, Takahashi M, Kimura M, Okamura A. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb. 2006 Jun;13(3):123-129.
9. Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent * - указано МНН лекарственного препарата, в случае отсутствия такого наименования указано химическое наименование лекарственного препарата, а при отсутствии МНН и химического наименований лекарственного препарата указано ТН лекарственного препарата ** - лекарственные препараты, назначаемые по решению врачебной комиссии ЛПУ with administration of statins. Endocr J. 2005 Jun;52(3):369-372.
10. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus. J Atheroscler Thromb. 2006 Apr;13(2):95-100.
11. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group: Report of the study: Long-term evaluation for efficacy and safety of new HMG-CoA reductase inhibitor CI-981 in Japanese hypercholesterolemia patients. A 52-week open label study (in Japanese). Prog Med. 1999; 19:2123-2160.
12. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients. J Am Coll Cardiol. 2010 Mar 23;55(12):1209-1216.
13. Nacasch N, Korzets Z. Worsening of hyperglycemia due to atorvastatin in renal transplant patients. NDT Plus. 2009; 2: 392-394.
14. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the angloscandinavial cardiac outcomes trial. Lipid lowering arm (ASCOT- LLA): a multicentre randomized controlled trial. Lancet. 2003 Apr 5;361(9364):114911-11458.
15. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton- Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004 Aug 21-27;364(9435):685-696.
16. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. Diabetes Care. 2009 Oct;32(10):1924-1929.
17. Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I, Isles C, Lorimer A. R, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the Development of Diabetes Mellitus. Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study. Circulation. 2001 Jan 23;103(3):3573-62.
18. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010 Feb 27;375(9716):735-742. Epub 2010 Feb 16
19. Schneider D. Statin Medications and New Onset Diabetes. Posted September 9, 2011. Available from: www.betacelldiabetes. org/expertblog.
20. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Canon CP. High dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 Substudy. Circulation. 2004; 110(Suppl I):S834.
21. Osaki F, Ikeda S, Suehiro T, Ota K, Ui K, Kunon Y, Hashimoto K. Effect of statins on glucose metabolism (in Japanese, with title translated by the authors). Jpn J Clin Exp Med. 2005; 82:359-363.
22. Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet. 2002 Jun 22;359(9324):2195-8.
23. Yamazaki M, Suzuki H, Hanano M, Tokui T, Kamai T, Sugiyama Y. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol. 1993 Jan;264(1 Pt 1):G36-44.
24. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of Atorvastatin and Pravastatin on Signal Transduction related to Glucose Uptake in 3T3L1 Adipocytes. J Pharmacol Sci. 2008 May;107(1):80-89. Epub 2008 May 9.
25. Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, Sachdeva R, Kesan SH, Mehta JL. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 2009 Mar;57(3):495-499.
Review
For citations:
Aleksandrov A.A., Yadrikhinskaya M.N., Kukharenko S.S., Shatskaya O.A. Statins and diabetes mellitus: price of collaboration. Diabetes mellitus. 2012;15(2):70-76. (In Russ.) https://doi.org/10.14341/2072-0351-5522
Views:
38471
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
